The 21 linked references in paper A. Mudunov, A. Ahundov, M. Bolotin, T. Braunschweig, А. Мудунов, А. Ахундов, М. Болотин, Т. Брауншвейг (2018) “Новые результаты исследования плоскоклеточного рака головы и шеи в отношении классификации и системной терапии. Расширенный обзор // An update on head and neck squamous cell carcinoma in respect to classification and systemic therapy. Extended review” / spz:neicon:ogsh:y:2018:i:1:p:48-55

  1. Marur S., D'Souza G., Westra W.H., Forastiere A.A. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010;11(8):781–9. DOI: 10.1016/S1470-2045(10)70017-6.
  2. Брауншвейг Т., Левандровски А., Смеетс Д., Болотин М.В. Плоскоклеточный рак головы и шеи: новые перспективы лечения? Опухоли головы и шеи 2013;(3):4–10. [Braunschweig T., Lewandrowski A., Smeets D., Bolotin M.V. Squamous cell carcinoma of the head and neck: new avenues of treatment? Opukholi golovy i shei = Head and Neck Tumors 2013;(3):4–10. (In Russ.)]. DOI: 10.17650/2222-1468-2013-0-3-4-10.
  3. Forman D., de Martel C., Lacey C.J. et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30(5): F12–23. DOI: 10.1016/j.vaccine.2012.07.055.
  4. Hammarstedt L., Lindquist D., Dahlstrand H. et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 2006;119(11): 2620–3. DOI: 10.1002/ijc.22177.
  5. Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5):E359–86. DOI: 10.1002/ijc.29210.
  6. Bishop J.A., Guo T.W., Smith D.F. et al. Human papillomavirus-related carcinomas of the sinonasal tract. Am J Surg Pathol 2013;37(2):185–92. DOI: 10.1097/ PAS.0b013e3182698673.
  7. Shaughnessy J.N., Farghaly H., Wilson L. et al. HPV: a factor in organ preservation for locally advanced larynx and hypopharynx cancer? Am J Otolaryngol 2014;35(1):19–24. DOI: 10.1016/j.amjoto. 2013.08.006.
  8. Coordes A., Lenz K., Qian X. et al. Metaanalysis of survival in patients with HNSCC discriminates risk depending on combined HPV and p16 status. Eur Arch Otorhinolaryngol 2016;273(8):2157–69. DOI: 10.1007/s00405-015-3728-0.
  9. Badoual C., Hans S., Merillon N. et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73(1):128–38. DOI: 10.1158/0008-5472.CAN-12-2606.
  10. Lewis J.S. Jr., Beadle B., Bishop J.A. et al. Human papillomavirus testing in head and neck carcinomas: Guideline from the College of American Pathologists. Arch Pathol Lab Med 2017; Dec 18. DOI: 10.5858/ arpa.2017-0286-CP.
  11. Ndiaye C., Mena M., Alemany L. et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol 2014;15(12):1319–31. DOI: 10.1016/S1470-2045(14)70471-1.
  12. Ang K.K., Harris J., Wheeler R. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363(1):24–35. DOI: 10.1056/ NEJMoa0912217.
  13. Carozzi F., Gillio-Tos A., Confortini M. et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPVpositive women according to baseline p16INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2013;14(2):168–76. DOI: 10.1016/S14702045(12)70529-6.
  14. Muller S., Khuri F.R., Konoet S.A. et al. HPV positive squamous cell carcinoma of the oropharynx. Are we observing an unusual pattern of metastases? Head Neck Pathol 2012;6(3):336–44. DOI: 10.1007/s12105-012-0355-6.
  15. Adelstein D., Gillison M.L., Pfister D.G. et al. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. J Natl Compr Canc Netw 2017;15(6):761–70. DOI: 10.6004/jnccn.2017.0101.
  16. Economopoulou P., Perisanidis C., Giotakis E.I., Psyrri A. The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Ann Transl Med 2016;4(9):173. DOI: 10.21037/atm.2016.03.34.
  17. Chung C.H., Frampton G.M., Chalmers Z.R. et al. Genomic profiling of squamous malignancies across anatomic sites. J Clin Oncol 2017;35(15):11512. DOI: 10.1200/ JCO.2017.35.15_suppl.11512.
  18. Thallinger C., Fureder T., Preusser M. et al. Review of cancer treatment with immune checkpoint inhibitors: Current concepts, expectations, limitations and pitfalls. Wien Klin Wochenschr 2018;130(3–4):85–91. DOI: 10.1007/ s00508-017-1285-9.
  19. Scheel A.H., Dietel M., Heukamp L.C. et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 2016;29(10):1165–72. DOI: 10.1038/ modpathol.2016.117.
  20. Hirsch F.R., McElhinny A., Stanforth D. et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol 2017;12(2):208– 22. DOI: 10.1016/j.jtho.2016.11.2228.
  21. Ferris R.L., Clump D.A., Ohr J. et al. Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC). Ann Oncol 2017;28(Suppl 5). DOI: 10.1093/annonc/ mdx374.014.